MRK's decision to stop the late-stage HYPERION study on PAH drug Winrevair ahead of time comes after evaluating the drug's ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the Phase 3 HYPERION study evaluating ...

The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...

The Nasdaq Composite and S&P 500 rose on Tuesday due to strong gains from Palantir as market focused on latest trade news.

Robert F. Kennedy Jr., Trump's pick to head the Department of Health and Human Services, faces scrutiny for fees he may earn from lawsuits against Merck.

Gossamer Bio Inc. has released new data showing its inhaled kinase inhibitor, seralutinib, has long-lasting effects on ...

Coulter Partners, the global expert in building leadership teams for Health, Science and Technology innovation businesses, ...

Facing intense scrutiny from senators over his potential profit from vaccine lawsuits while serving as the nation's health ...

The HYPERION study will be stopped early due to positive efficacy data from across the sotatercept clinical program.